Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.

Clinical lung cancer - 1 Nov 2022

Girard Nicolas, Minchom Anna, Ou Sai-Hong Ignatius, Gadgeel Shirish M, Trigo José, Viteri Santiago, Bauml Joshua M, Londhe Anil, Mahadevia Parthiv, Bazhenova Lyudmila

Abstract excerpt

INTRODUCTION: The activity of immune checkpoint inhibitors (ICIs) in NSCLC harboring EGFR exon 20 insertion mutations (ex20ins) has not been closely examined due to the frequent exclusion of patients with EGFR mutations from large immunotherapy-based NSCLC trials. PATIENTS AND METHODS: A real-world, retrospective study was conducted to compare outcomes of ICI-treated patients with EGFR ex20ins and wildtype NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 36085282
DOI: 10.1016/j.cllc.2022.07.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.PMID 36085282Read ↗

Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.Semantic proximity Read ↗

Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations.Semantic proximity Read ↗

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenSemantic proximity Read ↗

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.Semantic proximity Read ↗

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read ↗

The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidationSemantic proximity Read ↗

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertionSemantic proximity Read ↗

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.